Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,069.00 | 14.40 | -0.16% |
| CAC 40 | 8,103.85 | 17.22 | -0.21% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,442.41 | 79.73 | 0.16% |
| FTSE 100 | 9,889.22 | 23.25 | 0.24% |
| HKSE | 25,818.93 | 44.79 | 0.17% |
| NASDAQ | 23,561.84 | 133.02 | 0.57% |
| Nikkei 225 | 50,344.10 | 68.77 | -0.14% |
| NZX 50 Index | 13,529.06 | 11.33 | 0.08% |
| S&P 500 | 6,909.79 | 31.30 | 0.46% |
| S&P/ASX 200 | 8,762.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,940.95 | 20.97 | 0.53% |